Unadjusted Analysis of Mortality, Need for Mitral Reoperation, and
Progression of Mitral Regurgitation
Mean follow up for mortality was 72.7 ± 38.9 months and was complete in
all 410 patients. Thirty-day mortality was 1.5% in the ST group and
0.4% in the RAT group and was not statistically significantly different
between groups (Odds Ratio (OR) 0.24, 95% CI 0.02-2.7, p=0.25).
Overall, incidence of death was 7.4% in the ST group and 1.8% in the
RAT group (OR 0.23, 95% CI 0.08-0.69, p=0.009). Kaplan-Meier estimates
of survival at 1, 3, 5, and 10 years were 96.3, 93.0, 93.0, and 91.4%
for the ST group and 99.3, 98.9, 98.4, and 97.0% for the RAT group
(Log-Rank p = 0.004, Figure 1 and Supplemental Table
1 ).
Mean follow up for need for MV reoperation was 59.7 ± 39.0 months and
was complete in 313 (76.3%) patients. Overall incidence of need for
reoperation was 6.1% in the RAT group and 7.1% in the ST group (OR
0.85, 95% CI 0.33-2.20, p=0.74). The cumulative incidence of need for
MV reoperation with death as a competing outcome at 1, 3, and 5 years
were 5.8, 9.7, and 9.7% for the ST group and 2.3, 6.3, and 11.7% for
the RAT group (Grey’s Test for Equality of Cumulative Incidence
Functions, p=0.94, Figure 2 and Supplemental Table 1 ).
Mean follow up for progression of mitral regurgitation two or more
grades was 20.3 ± 21.4 months and was complete in 310 (75.6%) of
patients. Overall incidence of progression of MR was 8.5% in the RAT
group and 10.3% in the ST group (OR 0.80, 95% CI 0.36-1.81, p=0.67).
The cumulative incidence of progression of MR with death as a competing
outcome at 1, 3, and 5 years were 5.6, 12.1, and 36.7% for the ST group
and 3.6, 9.7, and 22.5% for the RAT group (Grey’s Test for Equality of
Cumulative Incidence Functions, p=0.53, Figure 3 andSupplemental Table 1 ).